BioSpace News Archive

Company to showcase market leadership with comprehensive Synapse portfolio, robust AI capabilities, and #AskIndustry panel participation

Three initiatives will seek to develop clinical-level interventions around safe weapon storage, suicide-prevention and risk prediction [20-June-2019] OAKLAND, Calif. , June 20, 2019 /PRNewswire/ -- Kaiser Permanente, the nation’s largest nonprofit, integrated health system, will fund three clinical research studies that focus on how clinicians can help prevent firearm

Company will continue to leverage leadership in Brain-Immune-Gut axis biology to develop novel categories of therapeutics

LifeFlow, a simple new device for rapid delivery of a targeted fluid bolus, is one of the medical innovations that was showcased in front of thousands of healthcare providers at Premier Inc.'s 2019 Breakthroughs Conference and Exhibition on June 18.

OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part.

New Aplio a-series Delivers Advanced Applications in Cardiac Imaging and Ergonomics at Affordable Price Point

Cyxone, a Swedish biotech in autoimmune diseases, announced that the company starts its first-in-human, phase I, clinical trial with drug candidate T20K for the treatment of multiple sclerosis immediately following the authorities’ approval.

As patients increasingly seek care outside of a healthcare organization’s homepage, the healthcare sector recognizes its need for improved off-website engagement data monitoring.

Verastem, Inc., a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that Robert Forrester has decided to step down as President and Chief Executive Officer. Mr. Forrester has agreed to continue serving Verastem Oncology in an advisory capacity.

Investments from this round will be used to advance the development and deployment of the Xealth platform for digital health programs.